Cibus Inc
CBUS
NASDAQ
Biotechnology
$1.77
USD
-0.13 (-6.84%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $148.47M
Volume 331.9K
About Cibus Inc
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 118 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
CEO
Dr. Peter Beetham
HQ
San Diego, CALIFORNIA, US
Founded
2017
Employees
118
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on CBUS.
Based on Quantli research · SEC filings · as of Q1 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
-9.8%
-114.6 pp
Gross Margin (TTM)
100.0%
0.0 pp
Operating Margin (TTM)
-1588.4%
+4337.0 pp
Net Margin (TTM)
-2427.2%
+3995.3 pp
ROE (TTM)
-293.2%
+119.4 pp
Free Cash Flow (TTM)
$-50.65M
—
Financial Snapshot
Revenue
$4.29M
-9.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-104.03M
+65.9%
YoY
Operating Cash Flow
$-50.25M
+10.9%
YoY
Key Statistics
Open
$1.73
Previous Close
$1.90
Day Range
$1.53 - $1.79
52 Week Range
$1.09 - $4.19
Volume
331.9K
Average Volume (10 Days)
150.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$148.47M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
34.64
Price / Book
4.18
Financial Highlights
Profit Margin
-2427.2%
Return on Assets
-32.1%
Return on Equity
-293.2%
Revenue (TTM)
$4.29M
Net Income (TTM)
$-104.03M
Diluted EPS (TTM)
-$1.97
Total Cash (MRQ)
$30.32M
Levered FCF (TTM)
$-50.65M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Similar Stocks
CUE
Cue Biopharma Inc
$34.20
▲ +10.0%
INDP
Indaptus Therapeutics Inc
$1.07
▲ +0.9%
VTVT
vTv Therapeutics Inc
$30.12
▼ -2.4%
EQ
Equillium Inc
$2.36
▲ +17.4%
OTLK
Outlook Therapeutics Inc
$0.7600
▼ -14.9%
GNLX
Genelux Corp
$2.74
▲ +4.2%
IMDX
Insight Molecular Diagnostics Inc
$4.32
▲ +16.4%
BDTX
Black Diamond Therapeutics Inc
$2.02
▲ 0.0%
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 11
Est. EPS
Adjusted consensus estimate
-$0.24